A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

March 21, 2022 updated by: Sanofi

A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus

Primary Objective:

To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes mellitus.

Secondary Objective:

To demonstrate that treatment with HOE901-U300 compared to Lantus provides:

  • Lower incidence rate of nocturnal symptomatic hypoglycemia;
  • Better glucose control coverage during the last hours of CGM before next basal-insulin dosing;
  • Less variability in CGM profile.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The maximum study duration per participant was to be of approximately 20 weeks that consisted of an up to a 4-week screening and CGM training period including a 1-2 week baseline (blinded) CGM performance (allowed for re-training), a 14-week open-label, comparative treatment period allowing for dose titration in both basal and meal-time insulin and including a 1-2 week end-of treatment blinded CGM collection with fixed dose of HOE901-U300 and Lantus, and a 2 day post treatment follow-up period.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
638

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Puerto Rico
      • Manati, Puerto Rico, 00674
        • Investigational Site Number 840-111
  • United States
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Investigational Site Number 840-151
    • California
      • Concord, California, United States, 94520-2270
        • Investigational Site Number 840-071
      • Escondido, California, United States, 92025
        • Investigational Site Number 840-149
      • Fresno, California, United States, 93720
        • Investigational Site Number 840-004
      • Greenbrae, California, United States, 94904
        • Investigational Site Number 840-110
      • La Jolla, California, United States, 92037
        • Investigational Site Number 840-124
      • La Mesa, California, United States, 91942
        • Investigational Site Number 840-030
      • Los Angeles, California, United States, 90036
        • Investigational Site Number 840-044
      • Los Angeles, California, United States, 90057
        • Investigational Site Number 840-022
      • Los Gatos, California, United States, 95032
        • Investigational Site Number 840-129
      • Northridge, California, United States, 91325
        • Investigational Site Number 840-024
      • Pomona, California, United States, 91766
        • Investigational Site Number 840-069
      • Pomona, California, United States, 91767
        • Investigational Site Number 840-090
      • Rolling Hills Estates, California, United States, 90274
        • Investigational Site Number 840-132
      • San Jose, California, United States, 95148
        • Investigational Site Number 840-130
      • San Ramon, California, United States, 94583
        • Investigational Site Number 840-055
      • Santa Barbara, California, United States
        • Investigational Site Number 840-028
      • Tarzana, California, United States, 91356
        • Investigational Site Number 840-063
      • Tustin, California, United States, 92780-6953
        • Investigational Site Number 840-138
      • Ventura, California, United States, 93003
        • Investigational Site Number 840-016
    • Colorado
      • Denver, Colorado, United States, 80209
        • Investigational Site Number 840-039
      • Denver, Colorado, United States, 80246
        • Investigational Site Number 840-021
      • Denver, Colorado, United States, 80262
        • Investigational Site Number 840-070
      • Englewood, Colorado, United States, 80113
        • Investigational Site Number 840-046
    • Florida
      • Coral Gables, Florida, United States, 33124
        • Investigational Site Number 840-072
      • Hialeah, Florida, United States, 33016
        • Investigational Site Number 840-133
      • Maitland, Florida, United States, 32751
        • Investigational Site Number 840-137
      • Miami, Florida, United States, 33155
        • Investigational Site Number 840-049
      • Miami, Florida, United States, 33176
        • Investigational Site Number 840-076
      • New Port Richey, Florida, United States, 34652
        • Investigational Site Number 840-023
      • Ocoee, Florida, United States, 34761
        • Investigational Site Number 840-053
      • Ormond Beach, Florida, United States, 32174
        • Investigational Site Number 840-112
      • Palm Harbor, Florida, United States, 34684
        • Investigational Site Number 840-018
      • Port Charlotte, Florida, United States, 33952
        • Investigational Site Number 840-047
      • Tampa, Florida, United States, 33612
        • Investigational Site Number 840-114
      • West Palm Beach, Florida, United States, 33401
        • Investigational Site Number 840-036
    • Georgia
      • Atlanta, Georgia, United States, 30318
        • Investigational Site Number 840-001
      • Columbus, Georgia, United States, 31904
        • Investigational Site Number 840-064
      • Lawrenceville, Georgia, United States, 30046
        • Investigational Site Number 840-012
      • Roswell, Georgia, United States, 30076
        • Investigational Site Number 840-008
      • Stockbridge, Georgia, United States, 30281
        • Investigational Site Number 840-014
    • Idaho
      • Idaho Falls, Idaho, United States, 83404
        • Investigational Site Number 840-060
    • Illinois
      • Arlington Heights, Illinois, United States, 60005
        • Investigational Site Number 840-125
      • Chicago, Illinois, United States, 60612
        • Investigational Site Number 840-011
      • Crystal Lake, Illinois, United States, 60012
        • Investigational Site Number 840-134
    • Iowa
      • West Des Moines, Iowa, United States, 50265
        • Investigational Site Number 840-002
    • Kansas
      • Wichita, Kansas, United States, 67226
        • Investigational Site Number 840-073
    • Kentucky
      • Covington, Kentucky, United States, 41011
        • Investigational Site Number 840-062
      • Lexington, Kentucky, United States, 40503
        • Investigational Site Number 840-042
    • Louisiana
      • Metairie, Louisiana, United States, 70006
        • Investigational Site Number 840-009
      • New Orleans, Louisiana, United States, 70115
        • Investigational Site Number 840-032
    • Maryland
      • Hyattsville, Maryland, United States, 20782
        • Investigational Site Number 840-054
      • Rockville, Maryland, United States, 20852
        • Investigational Site Number 840-006
    • Massachusetts
      • Framingham, Massachusetts, United States, 01702
        • Investigational Site Number 840-157
      • Waltham, Massachusetts, United States, 02453
        • Investigational Site Number 840-122
    • Michigan
      • Flint, Michigan, United States, 48532
        • Investigational Site Number 840-037
    • Montana
      • Billings, Montana, United States, 59101
        • Investigational Site Number 840-067
    • Nebraska
      • Lincoln, Nebraska, United States, 68526
        • Investigational Site Number 840-094
      • Omaha, Nebraska, United States, 68114
        • Investigational Site Number 840-033
      • Omaha, Nebraska, United States, 68124
        • Investigational Site Number 840-142
    • Nevada
      • Henderson, Nevada, United States, 89052
        • Investigational Site Number 840-040
      • Las Vegas, Nevada, United States, 89148
        • Investigational Site Number 840-017
    • New York
      • New York, New York, United States, 10001
        • Investigational Site Number 840-102
      • New York, New York, United States, 10029
        • Investigational Site Number 840-108
      • Staten Island, New York, United States, 10301-3914
        • Investigational Site Number 840-109
    • North Carolina
      • Greenville, North Carolina, United States, 27834
        • Investigational Site Number 840-045
      • Morehead City, North Carolina, United States, 28557
        • Investigational Site Number 840-010
      • Morehead City, North Carolina, United States, 28557
        • Investigational Site Number 840-080
    • North Dakota
      • Fargo, North Dakota, United States, 58103
        • Investigational Site Number 840-051
    • Ohio
      • Columbus, Ohio, United States, 43203
        • Investigational Site Number 840-123
      • Mentor, Ohio, United States, 44060
        • Investigational Site Number 840-104
    • Oklahoma
      • Norman, Oklahoma, United States, 73069
        • Investigational Site Number 840-079
    • Oregon
      • Bend, Oregon, United States, 97702
        • Investigational Site Number 840-162
      • Portland, Oregon, United States, 97210
        • Investigational Site Number 840-096
    • Tennessee
      • Chattanooga, Tennessee, United States, 37411
        • Investigational Site Number 840-058
    • Texas
      • Dallas, Texas, United States, 75230
        • Investigational Site Number 840-003
      • Dallas, Texas, United States, 75231
        • Investigational Site Number 840-019
      • Dallas, Texas, United States, 75235
        • Investigational Site Number 840-075
      • Dallas, Texas, United States, 75246
        • Investigational Site Number 840-005
      • Dallas, Texas, United States, 75246
        • Investigational Site Number 840-013
      • El Paso, Texas, United States, 79925
        • Investigational Site Number 840-153
      • Fort Worth, Texas, United States, 76132
        • Investigational Site Number 840-026
      • Houston, Texas, United States, 77024
        • Investigational Site Number 840-081
      • Houston, Texas, United States, 77043
        • Investigational Site Number 840-160
      • Houston, Texas, United States, 77079
        • Investigational Site Number 840-156
      • Houston, Texas, United States, 77089
        • Investigational Site Number 840-152
      • Houston, Texas, United States, 77095
        • Investigational Site Number 840-031
      • Lufkin, Texas, United States, 75904
        • Investigational Site Number 840-140
      • Mesquite, Texas, United States, 75149
        • Investigational Site Number 840-029
      • North Richland Hills, Texas, United States, 76180
        • Investigational Site Number 840-048
      • Pearland, Texas, United States, 77584
        • Investigational Site Number 840-150
    • Utah
      • Murray, Utah, United States, 84123
        • Investigational Site Number 840-083
      • Ogden, Utah, United States, 84405
        • Investigational Site Number 840-101
      • Salt Lake City, Utah, United States, 84102
        • Investigational Site Number 840-097
    • Vermont
      • Bennington, Vermont, United States, 05201
        • Investigational Site Number 840-143
      • Burlington, Vermont, United States, 05405
        • Investigational Site Number 840-056
    • Washington
      • Renton, Washington, United States, 98055
        • Investigational Site Number 840-015
      • Spokane, Washington, United States, 99207
        • Investigational Site Number 840-074
    • West Virginia
      • Bridgeport, West Virginia, United States, 26330
        • Investigational Site Number 840-139

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  • Adult participants (male and female) with type 1 diabetes mellitus (T1DM).
  • Signed written informed consent.

Exclusion criteria:

  • Age <18 years or >70 years.
  • Fasting c-peptide ≥0.3 nmol/L as per source document or central lab test at Visit 1.
  • Glycated hemoglobin (HbA1c) ≤ 6.5 % or ≥ 10.0% via central lab test at Visit 1.
  • Participants who experienced none of episode of documented symptomatic and/or severe hypoglycemia (as per the American Diabetes Association (ADA) classification) during the past month prior to screening.
  • Participants who experienced >1 episode of severe hypoglycemia resulting in coma/seizures during the last 12 months before screening.
  • Participants received less than 1 year treatment with basal plus mealtime insulin.
  • Used any basal insulins other than long-acting insulin analogs (ie, Lantus, Toujeo, Levemir, and Tresiba) in the past 3 months before screening.
  • Required >80 U/day basal insulin analogs or not on stable dose (±20% total dose) within 30 days prior to screening.
  • Used fewer than 2 injections of rapid-acting insulin analog per day within 30 days prior to screening.
  • Used human regular insulin as mealtime insulin within 30 days prior to screening.
  • Used an insulin pump during the last 6 months before screening.
  • History of unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to required treatment (e.g., laser, surgical treatment, or injectable drugs) during the study period.
  • Pregnant or breast-feeding women or planned pregnancy during the duration of the study.
  • Use of any other investigational drug(s) within 1 month or 5 half-lives, whichever was longer prior to screening.
  • Inappropriate CGM use during screening period evidenced by failure to obtain a minimum of 4 days of usable records by the end of screening.
  • Noncompliance with self-monitored plasma glucose (SMPG) performance evidenced by failure to demonstrate at least 5 days of 5 point SMPG records by the end of screening.

The above information is not intended to contain all considerations relevant to a participants's potential participation in a clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: HOE901-U300
HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
Drug: HOE901-U300 (Insulin Glargine 300 U/ml)
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
Other Names:
  • Toujeo
Drug: Mandated back ground therapy
Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Active Comparator: Lantus
Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
Drug: Mandated back ground therapy
Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Drug: Lantus (Insulin Glargine 100 U/ml)
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
Other Names:
  • HOE901-U100

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM
Time Frame: During Week 15 and/or 16
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted least square (LS) means and standard error (SE) were obtained from a generalized linear model with identity link including post baseline CGM assessment during Week 15 (and/or Week 16).
During Week 15 and/or 16

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Documented Symptomatic Nocturnal Hypoglycemia
Time Frame: Baseline up to Week 16
Documented symptomatic nocturnal hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by SMPG <=70 mg/dL that occurred between 00:00 and 05:59 hours as reported on the hypoglycemia electronic case report form (eCRF).
Baseline up to Week 16
Documented Symptomatic Nocturnal Hypoglycemia Event Rate Per Participant-Year
Time Frame: Baseline up to Week 16
Documented symptomatic nocturnal hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by SMPG <=70 mg/dL that occurred between 00:00 and 05:59 hours as reported on the hypoglycemia eCRF.
Baseline up to Week 16
Mean Change From Baseline in Glucose Level During Last 4 Hours of CGM Data Collection Prior to the Next Day Basal Insulin Injection During Week 15 and/or Week 16
Time Frame: Baseline, during Week 15 and/or Week 16
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessment during the last 4 hours prior to the next day's basal insulin injection during Week 15 (and/or Week 16).
Baseline, during Week 15 and/or Week 16
Percentage of Time Glucose Concentrations Within the Target Range of 70 to 140 mg/dL During Last 4 Hours of CGM Data Collection Prior to Next Day Basal Insulin Injection
Time Frame: During Week 15 and/or Week 16
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessment during the last 4 hours prior to the next day's basal insulin injection during Week 15 (and/or Week 16).
During Week 15 and/or Week 16
Coefficient of Variation (CV%) in Mean CGM Glucose
Time Frame: During Week 15 and/or Week 16
CV% was a measure of spread of variability relative to mean of population. For CGM glucose values over 24 hours, CV% was measure of glycemic variability across 24-hour day and calculated for each period (total, within day and between days) as ratio of standard deviation of glucose values to mean of glucose values.
During Week 15 and/or Week 16

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change From Baseline in Daily Insulin Dose at Week 16
Time Frame: Baseline, Week 16
Change from Baseline at Week 16 for daily basal insulin dose and daily bolus insulin dose was reported.
Baseline, Week 16

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Sanofi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 5, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 19, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 19, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 18, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 18, 2016

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 23, 2016

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 28, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 21, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • LPS14587
  • U1111-1176-0936 (Other Identifier: UTN)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Diabetes Mellitus

Clinical Trials on HOE901-U300 (Insulin Glargine 300 U/ml)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings